---
layout: post
title: "Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:08:52 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-04753
original_published: 2020-03-09 00:00:00 +0000
significance: 8.00
---

# Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 09, 2020 00:00 UTC
**Document Number:** 2020-04753

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment." This draft guidance provides recommendations for the characterization, during product development, of local safety of topical drug products regarding the risk for contact dermatitis. These recommendations are specifically directed to development of topical new drug products intended for cutaneous application.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/03/09/2020-04753/contact-dermatitis-from-topical-drug-products-for-cutaneous-application-human-safety-assessment)
- API: https://www.federalregister.gov/api/v1/documents/2020-04753

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
